Minwoo Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Minwoo Lee has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chung-Hyun Cho
Seoul National University 4 Department of Biomedical Sciences and Pharmacology, College of Medicine Seoul, Republic of Korea
1 shared publication - Eunae You
Mass General Cancer Center Harvard Medical School 02129 Charlestown MA USA
1 shared publication - Jangho Jeong
Chung-Ang University 1 Department of Life Science Seoul, Republic of Korea
1 shared publication - Jin Kyung Rho
Department of Biochemistry and Molecular Biology, Brain Korea 21 Project, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
1 shared publication - Jinho Kim
Chung-Ang University 1 Department of Life Science Seoul, Republic of Korea
1 shared publication - Jung-Woong Kim
Department of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea
1 shared publication
Latest Publications
- 30 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
Stromal MTHFD2 Links Fibrotic Remodeling to Immune Evasion via Redox-Dependent Inflammatory Signaling in Lung Adenocarcinoma
Fibroblast activation and extracellular matrix stiffening are hallmarks of the fibrotic tumor microenvironment. Fibrotic microenvironmental remodeling is also linked to immune exclusion and evasion, suggesting that common microenvironmental signals might coordinate both fibrotic and inflammatory outputs. In this study, we identified methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) as a redox-sensitive metabolic regulator linking TGFβ-driven fibroblast activation to inflammatory signaling in lung adenocarcinoma. MTHFD2 was elevated in cancer-associated fibroblasts across multiple single-cell RNA sequencing datasets, and TGFβ induced MTHFD2 even under compliant matrix conditions, with matrix stiffening further enhancing its expression. Notably, although MTHFD2 knockdown suppressed both myofibroblastic and inflammatory programs, enforced expression was sufficient to drive inflammatory cytokine production even in the absence of TGFβ, and this response was further amplified by concomitant TGFβ signaling. These MTHFD2-mediated responses depended on redox perturbation rather than biosynthetic one-carbon metabolism, as they resisted formate supplementation but responded to pro-oxidants. Mechanistically, MTHFD2-driven redox imbalance promoted mitochondrial stress, cytosolic mitochondrial DNA accumulation, and activation of the cGAS–STING–NF-κB pathway, resulting in IL6 and IL8 production. Fibroblast-specific MTHFD2 knockdown suppressed paracrine programmed cell death ligand 1 (PD-L1) induction in tumor cells and inhibited tumor growth in vivo in an immune-dependent manner. Clinically, high stromal MTHFD2 correlated with epithelial PD-L1 expression and poor lung adenocarcinoma prognosis. Together, these findings identify stromal MTHFD2 as a redox-sensitive metabolic checkpoint linking fibrotic remodeling to immune evasion. Significance: Stromal MTHFD2 couples fibrotic remodeling to cGAS–STING-dependent inflammatory signaling and PD-L1 induction through redox-dependent cGAS–STING activation in lung cancer, creating a stromal niche that supports immune evasion.
- 30 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
Stromal MTHFD2 Links Fibrotic Remodeling to Immune Evasion via Redox-Dependent Inflammatory Signaling in Lung Adenocarcinoma
Fibroblast activation and extracellular matrix stiffening are hallmarks of the fibrotic tumor microenvironment. Fibrotic microenvironmental remodeling is also linked to immune exclusion and evasion, suggesting that common microenvironmental signals might coordinate both fibrotic and inflammatory outputs. In this study, we identified methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) as a redox-sensitive metabolic regulator linking TGFβ-driven fibroblast activation to inflammatory signaling in lung adenocarcinoma. MTHFD2 was elevated in cancer-associated fibroblasts across multiple single-cell RNA sequencing datasets, and TGFβ induced MTHFD2 even under compliant matrix conditions, with matrix stiffening further enhancing its expression. Notably, although MTHFD2 knockdown suppressed both myofibroblastic and inflammatory programs, enforced expression was sufficient to drive inflammatory cytokine production even in the absence of TGFβ, and this response was further amplified by concomitant TGFβ signaling. These MTHFD2-mediated responses depended on redox perturbation rather than biosynthetic one-carbon metabolism, as they resisted formate supplementation but responded to pro-oxidants. Mechanistically, MTHFD2-driven redox imbalance promoted mitochondrial stress, cytosolic mitochondrial DNA accumulation, and activation of the cGAS–STING–NF-κB pathway, resulting in IL6 and IL8 production. Fibroblast-specific MTHFD2 knockdown suppressed paracrine programmed cell death ligand 1 (PD-L1) induction in tumor cells and inhibited tumor growth in vivo in an immune-dependent manner. Clinically, high stromal MTHFD2 correlated with epithelial PD-L1 expression and poor lung adenocarcinoma prognosis. Together, these findings identify stromal MTHFD2 as a redox-sensitive metabolic checkpoint linking fibrotic remodeling to immune evasion. Significance: Stromal MTHFD2 couples fibrotic remodeling to cGAS–STING-dependent inflammatory signaling and PD-L1 induction through redox-dependent cGAS–STING activation in lung cancer, creating a stromal niche that supports immune evasion.